Cargando…

Clinical Activity of Selpercatinib in RET Mutant Pheochromocytoma-Case Reports

Activating RET gene alterations have been reported in solid tumors including the rare cancer, pheochromocytoma (PHEO) found sporadically and in familial multiple endocrine neoplasia type 2 (MEN2) syndromes. Selpercatinib is a highly selective and potent small molecule RET kinase inhibitor that has d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konda, Bhavana, Massarelli, Erminia, Wright, Jennifer, Soldatenkova, Victoria, Clifton-Bligh, Roderick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Tumor Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265711/ http://dx.doi.org/10.1210/jendso/bvab048.2034

Ejemplares similares

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
por: Tsang, Venessa, et al.
Publicado: (2022)

OR34-6 A Novel Mechanism of SDH-Deficient Tumorigenesis and Implications for Genetic Testing in Patients with Pheochromocytoma-Paraganglioma
por: De Sousa, Sunita M.C., et al.
Publicado: (2019)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

SUN-939 Case Report: Malignant Pheochromocytoma
por: Lima, Jose Viana, et al.
Publicado: (2020)

Composite Pheochromocytoma With Ganglioneuroblastoma: A Case Report
por: Pastor, Paola M Lockhart, et al.
Publicado: (2021)

Hypercalcemia in Pheochromocytoma: From MEN to VHL
por: Mittal, Madhukar, et al.
Publicado: (2021)

The diagnosis and management of pheochromocytoma and paraganglioma during pregnancy
por: Clifton-Bligh, Roderick J.
Publicado: (2023)

MON-915 Acute Abdominal Pain and the Pheochromocytoma
por: Weiner, Yotam, et al.
Publicado: (2020)

Recurrent Pheochromocytoma, as Component of Multiple Endocrine Neoplasia
por: Dominguez, Hydelene Beray, et al.
Publicado: (2021)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

SUN-902 Bradycardia as a Presentation of Malignant Pheochromocytoma
por: Saleem, Marwa, et al.
Publicado: (2020)

A Surprising Outcome of Metastatic Pheochromocytoma Misdiagnosed as Renal Cell Carcinoma: A Case Report
por: Monsour, Elio Paul, et al.
Publicado: (2021)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

SAT-316 MAX-Related Bilateral Pheochromocytoma Associated with Subclinical Adrenal Insufficiency: A Case Report
por: Lundgrin, Erika, et al.
Publicado: (2019)

SAT-313 Catecholamine-Induced Cardiomyopathy in Pheochromocytoma during Pregnancy
por: Barreiro, Margarita, et al.
Publicado: (2019)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

SUN-921 Indolent Presentation of Medullary Thyroid Cancer in a Patient with MEN Type 2B Due to a Germline RET M918T Mutationo
por: Kim, Stephanie, et al.
Publicado: (2020)

SUN-933 Lactic Acidosis as a Rare and Unusual Presentation of Pheochromocytoma
por: Mohammad, Nazar, et al.
Publicado: (2020)

Presentation of Pheochromocytoma, Papillary Thyroid Cancer and Hyperparathyroidism in Three Family Members
por: Ashorobi, Damilola, et al.
Publicado: (2021)

Using Multimodal Functional Imaging in the Management of SDHx-Related Pheochromocytoma and Paraganglioma
por: White, Gemma, et al.
Publicado: (2021)

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
por: Wirth, Lori J, et al.
Publicado: (2022)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

SUN-937 A Case of Two Pathologies: Primary Hyperaldosteronism with a History of Pheochromocytoma
por: Akamnonu, Chukwuka, et al.
Publicado: (2020)

SAT-317 The Importance of Accurate Genetic Diagnosis Highlighted in a Case of Recurrent Bilateral Pheochromocytomas
por: Choo, Kuan Swen, et al.
Publicado: (2019)

SUN-932 Successful Response of Temozolomide (TMZ) in two Patients with Metastatic Pheochromocytoma/Paragangliomas (PPGLs)
por: de Almeida, Tobias Skrebsky, et al.
Publicado: (2020)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

SAT-314 Malignant Pheochromocytoma: A Rare Neoplasm Easily Confounded with Metastasis and Associated with Lynch Syndrome
por: Miah, Mumtaheena, et al.
Publicado: (2019)

A Case of Renal Cell Carcinoma and Pheochromocytoma Due to Germline Inactivating Mutation in Fumarate Hydratase (FH)
por: Reda, Sarah Alicia, et al.
Publicado: (2021)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
por: Drilon, Alexander, et al.
Publicado: (2023)

SUN-910 High Enhancement Washout by CT Imaging Does Not Exclude Pheochromocytoma/Paraganglioma: Review of Two Cases
por: Erenler, Feyza, et al.
Publicado: (2020)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

SAT-310 (18)F-FDOPA PET/CT Accurately Identifies Pheochromocytoma in 70-Year-Old Male with MEN1
por: Tepede, Aisha, et al.
Publicado: (2019)

SAT-140 Determining the Undetermined: The Role of Tumor Tissue Staining for Interpretation of Inconclusive Genetic Testing Results in Patients with Pheochromocytomas and Paragangliomas
por: Khanna, Parul, et al.
Publicado: (2020)

OR29-3 High-specific-activity Iodine 131 Metaiodobenzylguanidine for the Treatment of Advanced Pheochromocytoma and Paraganglioma: A Real-world Study
por: Al-ward, Ruaa
Publicado: (2022)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
por: Porcelli, Tommaso, et al.
Publicado: (2023)

SUN-913 A MEN-2a Syndrome Index Case Presenting with Adrenergic Crisis and Cardiogenic Shock Due to Bilateral Pheochromocytoma
por: Salazar, Daniela, et al.
Publicado: (2020)

SAT-321 Bilateral Cortical Sparing Adrenalectomy For Treatment Of Pheochromocytoma In A MEN2-a Mutation Carrier: 19 Year Follow-up
por: de Almeida, Tobias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5h8u6dp15h52fanr3gtq3eqcol